Future Planet Capital

Lineat is a manufacturer specializing in fiber tape products, particularly focusing on carbon fiber tapes produced through aligned formable fiber technology. This innovative approach allows for the creation of aligned discontinuous fiber tapes that demonstrate mechanical performance comparable to traditional continuous fiber composites. By simplifying the composite manufacturing process, Lineat enhances formability and streamlines both manual and automated operations. Additionally, the company has implemented a closed-loop water circulation system aimed at improving lifecycle assessment (LCA), reflecting its commitment to sustainability in production practices.

NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy. The company develops both cell therapy and small molecule therapeutics primarily targeting cancer.

MicrofluidX Ltd is a company focused on advancing cell bioprocessing for autologous cell and gene therapy manufacturing. Founded in 2018 and headquartered in London, United Kingdom, the company has developed an innovative microfluidic bioprocessing system that integrates various cell culture functions, including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting within a single, automated, closed system. This technology addresses challenges related to process control, scalability, and cost in cell bioprocessing, enabling biologists to efficiently conduct process development by exploring numerous cell culture conditions.

Nuclera is developing a bench-top gene and protein printer.

Helix Technologies is developing a range of compact, high-performance, dielectric-loaded ceramic antennas for use in a wide range of demanding telecommunications and navigation applications. The use of the ceramic core enables the fabrication of antennas that are physically smaller than conventional antennas, behave much more effectively and predictably in a wide range of challenging user scenarios and have many compelling technical advantages

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Developer of a lipid nanoparticle platform intended to provide better RNA vaccines. The company creates lipid products for use in building RNA vaccines for various diseases and offers systematic delivery of RNA molecules using targeted nanocarriers to the immune system with more transportable, with broader capabilities, and fewer side effects, enabling patients to have access to better vaccines and treatments.

Lineat is a manufacturer specializing in fiber tape products, particularly focusing on carbon fiber tapes produced through aligned formable fiber technology. This innovative approach allows for the creation of aligned discontinuous fiber tapes that demonstrate mechanical performance comparable to traditional continuous fiber composites. By simplifying the composite manufacturing process, Lineat enhances formability and streamlines both manual and automated operations. Additionally, the company has implemented a closed-loop water circulation system aimed at improving lifecycle assessment (LCA), reflecting its commitment to sustainability in production practices.

Inition is a company based in Didcot, England, focused on decarbonizing battery production and making the process accessible across various levels of the industry. It has developed proprietary technology that simplifies the manufacturing of electrodes, significantly reducing energy consumption during production. This innovative approach also minimizes the factory space required for production, thereby lowering operational costs. By enhancing the efficiency of battery manufacturing, Inition aims to support industries in accelerating their transition to renewable energy solutions.

Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existing bio-design limits imposed by conventional peptide synthesis, with one universal process.

Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.

Nemesis Bioscience Ltd. is a biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic agents that restore antibiotic sensitivity in resistant microbial pathogens. Founded in 2014, the company specializes in its innovative Nemesis Symbiotics, which are designed to directly kill pathogenic microorganisms or enhance their susceptibility to existing antibiotics. This technology addresses all classes of antibiotics and various resistance mechanisms, aiming to prevent the spread of resistance genes and maintain the effectiveness of both current and future antibiotics. In addition to treating infections, Nemesis Bioscience's solutions also have potential applications in reducing chemotherapy toxicity and inactivating virulence factors. The company has received recognition for its entrepreneurial efforts, including an award from King’s College, Cambridge, and has filed multiple international patent applications to protect its inventions.

NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy. The company develops both cell therapy and small molecule therapeutics primarily targeting cancer.

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

MicrofluidX Ltd is a company focused on advancing cell bioprocessing for autologous cell and gene therapy manufacturing. Founded in 2018 and headquartered in London, United Kingdom, the company has developed an innovative microfluidic bioprocessing system that integrates various cell culture functions, including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting within a single, automated, closed system. This technology addresses challenges related to process control, scalability, and cost in cell bioprocessing, enabling biologists to efficiently conduct process development by exploring numerous cell culture conditions.

Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.

Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.

CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.

Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existing bio-design limits imposed by conventional peptide synthesis, with one universal process.

HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range of application areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market.

PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.

PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.

Nuclera is developing a bench-top gene and protein printer.

Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.

CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.

Nemesis Bioscience Ltd. is a biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic agents that restore antibiotic sensitivity in resistant microbial pathogens. Founded in 2014, the company specializes in its innovative Nemesis Symbiotics, which are designed to directly kill pathogenic microorganisms or enhance their susceptibility to existing antibiotics. This technology addresses all classes of antibiotics and various resistance mechanisms, aiming to prevent the spread of resistance genes and maintain the effectiveness of both current and future antibiotics. In addition to treating infections, Nemesis Bioscience's solutions also have potential applications in reducing chemotherapy toxicity and inactivating virulence factors. The company has received recognition for its entrepreneurial efforts, including an award from King’s College, Cambridge, and has filed multiple international patent applications to protect its inventions.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.

Oxford Advanced Surfaces Group Plc is a company that focuses on surface modification. When it comes to surface modification, we are the experts. As a team we have over 70 years of experience and over 30 patents in this field since our commercialisation out of the University of Oxford. Our team of scientists is highly skilled in the synthesis and formulation of Onto™ materials, so we design and optimise products to meet the needs of real industrial challenges.

Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.

Halo Neuroscience is a neurotechnology company based in San Francisco that focuses on enhancing human performance through innovative systems. Since its incorporation in 2013, the company has developed its flagship product, Halo Sport, which employs Neuropriming technology. This technology involves delivering electrical stimulation during physical training to enhance the brain's learning capacity, a state referred to as "hyperplasticity." By improving the connections between the brain and muscles, Halo Sport aims to accelerate skill acquisition and strength development, particularly for elite athletes. Through its advancements in neurotechnology, Halo Neuroscience seeks to help individuals maximize their potential in various performance domains.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Tokamak Solutions UK Ltd. engages in providing technology for fusion neutron source to transmute nuclear waste. The company was founded in 2009 and is based in Abingdon, United Kingdom.

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.

Nemesis Bioscience Ltd. is a biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic agents that restore antibiotic sensitivity in resistant microbial pathogens. Founded in 2014, the company specializes in its innovative Nemesis Symbiotics, which are designed to directly kill pathogenic microorganisms or enhance their susceptibility to existing antibiotics. This technology addresses all classes of antibiotics and various resistance mechanisms, aiming to prevent the spread of resistance genes and maintain the effectiveness of both current and future antibiotics. In addition to treating infections, Nemesis Bioscience's solutions also have potential applications in reducing chemotherapy toxicity and inactivating virulence factors. The company has received recognition for its entrepreneurial efforts, including an award from King’s College, Cambridge, and has filed multiple international patent applications to protect its inventions.

PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.

ProKyma Technologies Limited specializes in diagnostics services and life science applications using magnetic particles for various processes such as cell isolation, immunoassays, and DNA capture. Based in Salisbury, Wiltshire, United Kingdom, the company focuses on developing advanced cell separation technology to enhance molecular biology tests. A notable application of ProKyma's technology is its improved blood test for circulating tumor cells (CTCs), which aids in the early detection of cancer metastasis and monitoring therapeutic responses. The company, a spinout from Dstl Porton Down, leverages high-frequency ultrasound and magnetism to manipulate and purify biological cells from complex samples. This innovative approach has applications across clinical, food, environmental, and pharmaceutical sectors, ultimately enabling more effective patient treatment and cancer monitoring.

P2i Limited specializes in liquid repellent nano-coating technology, providing innovative solutions that enhance the performance of various products without altering their appearance or texture. Founded in 2003 and based in Abingdon, United Kingdom, P2i utilizes a unique pulsed plasma deposition process to create hydrophobic coatings that reduce the surface energy of materials, allowing liquids to bead up and roll off. This technology is applicable to a wide range of sectors, including electronics, textiles, lifestyle products, life sciences, filtration, energy, and military applications. P2i operates internationally, with facilities in the United States and Singapore, as well as application centers in China, serving customers looking to protect their products from water and other liquids.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

ProKyma Technologies Limited specializes in diagnostics services and life science applications using magnetic particles for various processes such as cell isolation, immunoassays, and DNA capture. Based in Salisbury, Wiltshire, United Kingdom, the company focuses on developing advanced cell separation technology to enhance molecular biology tests. A notable application of ProKyma's technology is its improved blood test for circulating tumor cells (CTCs), which aids in the early detection of cancer metastasis and monitoring therapeutic responses. The company, a spinout from Dstl Porton Down, leverages high-frequency ultrasound and magnetism to manipulate and purify biological cells from complex samples. This innovative approach has applications across clinical, food, environmental, and pharmaceutical sectors, ultimately enabling more effective patient treatment and cancer monitoring.

Inscentinel uses the exquisitely sensitive olfactory sense of bees to detect minute concentrations of volatile compounds such as explosives, drugs, or odours that indicate disease. The bees are held in a harness and can then be trained to recognize particular scents, in much the same way that sniffer dogs can be trained. In the presence of the odour for which they have been trained, the bees have a proboscis extension reflex, and this is then picked up by a camera and its associated software that then sends a signal to an operator or simply logs the data. A US patent has been granted and other patent applications are proceeding.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

ProKyma Technologies Limited specializes in diagnostics services and life science applications using magnetic particles for various processes such as cell isolation, immunoassays, and DNA capture. Based in Salisbury, Wiltshire, United Kingdom, the company focuses on developing advanced cell separation technology to enhance molecular biology tests. A notable application of ProKyma's technology is its improved blood test for circulating tumor cells (CTCs), which aids in the early detection of cancer metastasis and monitoring therapeutic responses. The company, a spinout from Dstl Porton Down, leverages high-frequency ultrasound and magnetism to manipulate and purify biological cells from complex samples. This innovative approach has applications across clinical, food, environmental, and pharmaceutical sectors, ultimately enabling more effective patient treatment and cancer monitoring.

Chameleon BioSurfaces specializes in advanced surface design technology for medical device manufacturers. The company focuses on creating tailored solutions to address specific challenges and opportunities within the medical device sector. Its innovative approach involves polymerizing coatings directly onto metal surfaces through a patented electrodeposition process. This technology allows for customization of the coatings, enabling them to be adapted to meet various clinical requirements. By collaborating closely with its clients, Chameleon BioSurfaces aims to enhance the performance and functionality of medical implants and devices.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.